INTRODUCTION
As a receptor for a diverse array of microbial constituents, CD14 plays a key role in the propagation of the innate immune response directed against microbial pathogens. The CD14 molecule is expressed as a 55 kDa glycosylphosphatidylinositol (GPI)-anchored protein on the surface of monocytes and neutrophils and as a soluble isoform in serum. CD14 is known to function as a receptor for constituents of Gram-negative bacteria (lipopolysaccharide or LPS, polyuronic acid), Grampositive bacteria (lipoteichoic acid, peptidoglycan) and mycobacteria (lipoarabinomannan). [1] [2] [3] Recognition of these constituents by CD14 triggers signal transduction through Toll-like receptors 2 and 4 leading to the release of pro-inflammatory cytokines, lipid mediators, coagulation factors and reactive intermediates. [4] [5] [6] This response, which functions to eliminate microbial pathogens in cases of localized infection, may lead to severe sepsis and septic shock in cases of bacteremia or endotoxemia. 7, 8 In such cases, inhibiting the innate response to infection by blocking CD14 function may reduce mortality or organ pathology as a result of sepsis and septic shock.
REVIEW OF ANTI-CD14 PRECLINICAL STUDIES
In rabbits and in Cynomolgus monkeys, monoclonal antibodies directed against CD14 have been shown to block the association of bacterial constituents with CD14 and, as a result, to attenuate the innate immune response. For example, in a repeat LPS challenge model conducted in rabbits, anti-CD14 treatment completely prevented mortality, renal necrosis and pulmonary injury when compared to an irrelevant control antibody. 9 In addition, the results of this study demonstrated that both prophylactic (prior to initial LPS challenge) and delayed (as late as 23 h after initial LPS challenge) regimens of anti-CD14 were equally protective. In contrast, anti-TNF treatment was IC14, a CD14 specific monoclonal antibody, is a potential treatment for patients with severe sepsis
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shown to prevent mortality only when administered prior to LPS challenge. Similar results were obtained in a Cynomolgus monkey endotoxin challenge model using the human CD14specific murine monoclonal antibody 28C5. The results of this study demonstrated that prophylactic 28C5 treatment inhibited hypotension, lung permeability and the release of pro-inflammatory cytokines in response to an endotoxin challenge. 10
TOXICOLOGY STUDIES WITH ANTI-CD14
A human-murine chimeric version of 28C5, termed IC14 is currently under development as a potential treatment for severe sepsis. Single-and repeat-dose toxicology studies using IC14 were conducted in Cynomolgus monkeys. The results of these studies demonstrated that IC14 was safe and well-tolerated at all doses tested (maximum dose tested was 25 mg/kg/day for 14 days). In the single dose study, histopathological examination revealed rare and slight mixed cell infiltration in the iris and ciliary body of animals receiving 2, 10 and 50 mg/kg IC14 and mononuclear cell infiltration in the meninges of animals receiving 10 and 50 mg/kg IC14. Both findings were judged toxicologically insignificant by the examining pathologist and resolved by the end of the 14-day recovery period. No treatment-related ocular or meningeal infiltrates were observed in the multiple administration toxicology study.
CLINICAL STUDIES WITH ANTI-CD14
Two clinical trials of IC14 in healthy subjects have been completed. The first trial was designed to assess safety and pharmacology in healthy subjects. The second trial was designed to determine whether IC14 treatment could block inflammatory responses in healthy volunteers challenged with a safe dose of LPS. The second trial has been described previously by Verbon et al. 11 
SAFETY AND PHARMACOLOGY IN HEALTHY SUBJECTS
Thirty healthy male subjects were enrolled in this double-blind, randomized placebo-controlled, dose-escalation trial. Written informed consent was obtained from all volunteers, and the study was approved by the institutional scientific and ethics committees. Each subject IC14 is a potential treatment for patients with severe sepsis 311 received a single administration of either placebo (vehicle, n = 10) or IC14 as an intravenous infusion. Dosages of IC14 were 0.03 mg/kg (n = 2), 0.1 mg/kg (n = 2), 0.3 mg/kg (n = 4), 1.0 mg/kg (n = 4), 2.0 mg/kg (n = 4) or 4.0 mg/kg (n = 4). The infusion duration was 10 min for 0.03, 0.1, 0.3 and 1.0 mg/kg IC14 dose groups, 60 min for the 2.0 mg/kg dose group and 120 min for the 4.0 mg/kg dose group. Clinical signs and symptoms were recorded throughout the study. To address the findings in the single-administration toxicology study, the presence or absence of cells in the anterior chamber of the eye was assessed using slit lamp ophthalmoscopy. The duration of follow-up was 29 days.
The results from analyses of adverse events and clinical laboratory data suggest that IC14 was well tolerated and not antigenic ( Table 1) . No evidence of accumulation of lymphocytes in the eyes or clinical signs and symptoms suggestive of meningeal inflammation (i.e. headache, meningismus, and photophobia) was observed. One subject receiving 1.0 mg/kg IC14 as a 10 min infusion developed a generalized, erythematous rash approximately 20 min after the receipt of test article. The rash and associated paresthesia were assessed by the investigator as being possibly treatment-related. The events resolved within 4 h after onset and did not require medical intervention. However, as a precautionary measure, subsequent infusions of IC14 and placebo in the 1.0 and 2.0 mg/kg, and 4.0 mg/kg cohorts were increased to 60 and 120 min, respectively. No other adverse events bearing a relationship to IC14 treatment as determined by the investigator were recorded.
Results from pharmacokinetic and pharmacodynamic analyses in this dose escalation trial indicated that peak serum concentration of IC14 increased as a function of dose as did both the duration of saturation of CD14 receptors on monocytes and the concentration of sCD14 ( Fig. 1) . At IC14 doses of 1.0 and 4.0 mg/kg, CD14 receptors on monocytes and granulocytes were greater than 80% saturated for approximately 24 and 72 h, respectively. This level of saturation was shown to maximally suppress IL-6 release in response to LPS in vitro. At a dose of 1.0 mg/kg IC14, the concentration of soluble CD14 increased by approximately 2-fold (i.e. increased from 1.5 to 3.0 ng/ml) 24 h after the administration of test article. At a dose of 4.0 mg/kg, the concentration of sCD14 increased by approximately 10-fold.
ANTI-CD14 IN HUMAN ENDOTOXEMIA
In a second trial, the ability of IC14 to inhibit systemic inflammatory responses in healthy volunteers challenged with a single dose of LPS was evaluated. The results of this trial have been described previously by Verbon et al. 11 Sixteen healthy male volunteers were enrolled in this randomized, double-blind placebo-controlled trial. Written informed consent was obtained from all volunteers, and the study was approved by the institutional scientific and ethics committees. Eight of the volunteers received IC14, and eight were given placebo. All participants were challenged with 4.0 ng/kg LPS 1 h after the end of the IC14 or placebo infusion. Symptoms were recorded throughout the study period and scored by incidence and severity (0 as absent, 1 as weak, 2 as moderate, and 3 as severe).
The results of this trial demonstrated that IC14 attenuated the incidence and severity of flu-like symptoms induced by LPS including chills, nausea, vomiting, myalgia and backache (Table 2 ). However, IC14 had no effect on the incidence or severity of headache.
The release of cytokines in response to LPS administration was also inhibited by IC14. IC14 treatment strongly reduced the LPS-induced release of TNF-α (P < 0.001), IL-6 (P < 0.001), and IL-10 (P < 0.001) in comparison to placebo (Fig. 2) . LPS-induced release of the antagonistic members of the pro-inflammatory cytokine network, sTNFR 1 and IL-1ra were delayed in the IC14 group relative to placebo (P < 0.05 for both, data not shown).
Finally, IC14 treatment inhibited the LPS-induced release of endothelial factors. Peak Von Willebrand factor levels in subjects treated with IC14 were significantly lower than in subjects treated with placebo (P < 0.05, data not shown). Although it was not statistically significant, a trend toward a reduction in peak soluble E-selectin concentration was also observed in the IC14 group relative to placebo.
ON-GOING STUDIES
A phase I trial in severe sepsis patients is currently in progress. This randomized, double-blind, placebo-controlled trial is being conducted in two parts. In the first half of the study, patients will receive a single administration of IC14 (1.0 mg/kg or 4.0 mg/kg) or placebo. Repeat doses of IC14 will be administered in the second half of the study.
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The dosages in the repeat-dose half of the study will be based on the single-dose safety and pharmacology results. An additional non-clinical study to determine whether CD14 antibody treatment impairs bacterial clearance in the presence or absence of antimicrobial therapy is also in progress. By inhibiting the innate inflammatory response, CD14 could potentially impair host defense against infection. Recent rabbit studies indicating that CD14 blockade attenuates bacterial clearance 12 and enhances tissue invasion by Shigella 13 in the absence of antimicrobial therapy support this hypothesis. As all sepsis patients enrolled in our phase I trial are required to be treated with antibiotics, the on-going bacterial clearance study in the presence and absence of antibiotic is designed to determine the relevance of these findings to our clinical program.
CONCLUSIONS
These studies have demonstrated that IC14 is an inhibitor of the systemic inflammatory response. In addition, IC14 was found to have favorable safety and pharmacological profiles in healthy volunteers. Taken together, these results support continued development of IC14 in severe sepsis. Clinical studies designed to assess the safety, pharmacology and efficacy of IC14 in patients with severe sepsis are in progress.
